• A proposed HHS rule to double the current patient limit of 100 for qualified physicians who prescribe buprenorphine treatment for opioid addicts. Earlier this month, HHS provided $94 million in new funding to 271 community health centers to bolster substance abuse services, focusing on medication-assisted treatment such as buprenorphine.
• New grant programs offered by the U.S. Substance Abuse and Mental Health Services Administration — $11 million for states to buy and distribute the fast-acting overdose rescue drug naloxone and train first responders and others in its use; and another $11 million for up to 11 states to expand medication-assisted treatment.
Obama also plans to sign a memorandum Tuesday creating an inter-agency task force that would, among other things, work to implement and enforce existing parity protections for coverage people get on the job, or plans they purchase under the Affordable Care Act.
“We’re talking about tens of millions of people” affected by these efforts, Frank said.
Other actions Obama plans to announce include:
• A proposed HHS rule to double the current patient limit of 100 for qualified physicians who prescribe buprenorphine treatment for opioid addicts. Earlier this month, HHS
BioDelivery Sciences International Inc. (NASDAQ:BDSI) also had a cluster of insider buying in the past two weeks. To start with, Director Charles J. Bramlage purchased 8,850 shares last Monday for $2.82 each, lifting his ownership to 28,150 shares. Chief Technology Officer Niraj Vasisht snapped up 1,000 units of common stock on March 18 at $2.80 apiece, which increased his direct ownership stake to 68,420 shares. Director Barry I. Feinberg bought a 10,000-share block on the same day at a weighted average price of $2.74, which is entirely held by the BIF Family Trust. The Director’s trust fund continues to hold a stake of 15,000 shares. Lastly, Ernest R. De Paolantonio, Chief Financial Officer, Secretary and Treasurer, purchased 4,000 shares a day earlier for $2.60 each, boosting his stake to 13,383 shares.
The push to curb opioid abuse by the National Governors’ Association could be an opportunity for Raleigh drug developer BioDelivery Sciences International (Nasdaq: BDSI) —at least that's what the company officials are hoping for.
Nearly 30,000 Americans die each year from the misuse and abuse of prescription opioids and heroin, and the governors’ association set a goal to reduce that figure.
Members of the National Governors Association came to Washington for their annual winter meeting with President Obama Monday, plan to restrict access to prescription painkillers and end the country’s deadly opioid epidemic.But the proposal, which drew bipartisan support from within the NGA over the weekend, received a less-than-enthusiastic response when presented to the president.According to the most recent data from the CDC 47,055 people died from a drug overdose in the U.S. in 2014 — more than any other year on record. Some 61 percent of those fatal overdoses involved opioids, mostly prescription painkillers like OxyContin or Percocet, and heroin. The CDC emphasizes the link between the significant increase in fatal opioid overdoses (up 200 percent since 2000) to the rise in opioid pill prescriptions in various parts of the country over the past several years According to the CDC, “Health care providers wrote 259 million prescriptions for painkillers in 2012, enough for every American adult to have a bottle of pills.”